Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.

dc.contributor.author

Davidson, Brittany A

dc.contributor.author

Secord, Angeles Alvarez

dc.coverage.spatial

New Zealand

dc.date.accessioned

2017-11-03T18:06:21Z

dc.date.available

2017-11-03T18:06:21Z

dc.date.issued

2014

dc.description.abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy or alone in women with primary and recurrent ovarian cancer. Antiangiogenic agents include monoclonal antibodies, tyrosine-kinase inhibitors, and peptibodies. Many of these agents, including bevacizumab, pazopanib, nintedanib, cediranib, and trebananib, have been evaluated in randomized Phase III clinical trials, and all have demonstrated a progression-free survival (PFS) benefit. Specifically, maintenance pazopanib was shown to improve PFS in women with newly diagnosed EOC. Pazopanib, an oral TKI, inhibits several kinase receptors, including those for vascular endothelial growth factor (-1,-2,-3), platelet-derived growth factor (-α and -β), and fibroblast growth factor. It also targets stem cell-factor receptor (c-kit), interleukin 2-inducible T-cell kinase, lymphocyte-specific protein tyrosine kinase, and colony-stimulating factor 1 receptor. Pazopanib has been investigated in several Phase II and III clinical trials, with results indicating a potential role in the management of EOC. This article provides an overview of pazopanib in the treatment of EOC.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/24648773

dc.identifier

ijwh-6-289

dc.identifier.issn

1179-1411

dc.identifier.uri

https://hdl.handle.net/10161/15735

dc.language

eng

dc.publisher

Informa UK Limited

dc.relation.ispartof

Int J Womens Health

dc.relation.isversionof

10.2147/IJWH.S49781

dc.subject

antiangiogenic agents

dc.subject

ovarian carcinoma

dc.subject

pazopanib

dc.title

Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.

dc.type

Journal article

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/24648773

pubs.begin-page

289

pubs.end-page

300

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Obstetrics and Gynecology

pubs.organisational-group

Obstetrics and Gynecology, Gynecologic Oncology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published online

pubs.volume

6

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.pdf
Size:
900.32 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.pdf
Size:
900.32 KB
Format:
Adobe Portable Document Format